KBC Group
RPRX icon

KBC Group’s Royalty Pharma RPRX Stock Holding History

KBC Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96M Buy
70,652
+7,413
+12% +$386K 0.01% 548
2026
Q1 		$3.03M Sell
63,239
-100,322
-61% -$4.39M 0.01% 573
2025
Q4 		$6.32M Sell
163,561
-24,404
-13% -$931K 0.01% 425
2025
Q3 		$6.63M Buy
187,965
+127,628
+212% +$4.62M 0.02% 410
2025
Q2 		$2.17M Buy
60,337
+932
+2% +$30.9K 0.01% 569
2025
Q1 		$1.85M Buy
59,405
+17,851
+43% +$566K 0.01% 603
2024
Q4 		$1.06M Hold
41,554
– – ﹤0.01% 756
2024
Q3 		$1.18M Buy
41,554
+16,081
+63% +$445K ﹤0.01% 669
2024
Q2 		$672K Hold
25,473
– – ﹤0.01% 700
2024
Q1 		$773K Sell
25,473
-4,553
-15% -$134K ﹤0.01% 693
2023
Q4 		$844K Buy
30,026
+370
+1% +$10.2K ﹤0.01% 702
2023
Q3 		$804K Sell
29,656
-59,800
-67% -$1.78M ﹤0.01% 703
2023
Q2 		$2.75M Sell
89,456
-6,313
-7% -$214K 0.01% 556
2023
Q1 		$3.45M Buy
95,769
+64,048
+202% +$2.37M 0.01% 560
2022
Q4 		$1.25M Buy
31,721
+24
+0.1% +$1K 0.01% 673
2022
Q3 		$1.27M Buy
31,697
+271
+0.9% +$11.6K 0.01% 630
2022
Q2 		$1.32M Sell
31,426
-14,766
-32% -$605K 0.01% 622
2022
Q1 		$1.8M Buy
46,192
+14,841
+47% +$583K 0.01% 603
2021
Q4 		$1.25M Buy
31,351
+2,493
+9% +$96.9K ﹤0.01% 688
2021
Q3 		$1.04M Sell
28,858
-1,271
-4% -$49.4K ﹤0.01% 750
2021
Q2 		$1.24M Sell
30,129
-1,473
-5% -$62.7K ﹤0.01% 737
2021
Q1 		$1.38M Sell
31,602
-51,781
-62% -$2.46M 0.01% 699
2020
Q4 		$4.17M Buy
+83,383
New +$3.54M 0.02% 498

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's RPRX Position: Q2 2026 in Review

KBC Group increased its Royalty Pharma (RPRX) stake by 12% in Q2 2026, buying an estimated $386K and bringing the position to 70,652 shares worth $3.96M. The position accounts for 0.01% of the portfolio, ranked #548.

KBC Group first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $6.63M in Q3 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • KBC Group held 70,652 shares of Royalty Pharma worth $3.96M as of Q2 2026.
  • KBC Group bought 7,413 Royalty Pharma shares in Q2 2026, an estimated $386K.
  • Royalty Pharma made up 0.01% of KBC Group's portfolio in Q2 2026, its #548 holding.
  • KBC Group first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • KBC Group's Royalty Pharma position peaked at $6.63M in Q3 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.